Moleculin Biotech Statistics
Total Valuation
MBRX has a market cap or net worth of $13.50 million. The enterprise value is $7.19 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MBRX has 2.04 million shares outstanding. The number of shares has increased by 528.05% in one year.
| Current Share Class | 2.04M |
| Shares Outstanding | 2.04M |
| Shares Change (YoY) | +528.05% |
| Shares Change (QoQ) | +135.60% |
| Owned by Insiders (%) | 2.25% |
| Owned by Institutions (%) | 4.64% |
| Float | 1.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39
| Current Ratio | 1.39 |
| Quick Ratio | 1.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -69.18% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -165.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.02M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Dividends & Yields
MBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -528.05% |
| Shareholder Yield | -528.05% |
| Earnings Yield | -380.78% |
| FCF Yield | -166.29% |
Analyst Forecast
The average price target for MBRX is $125.00, which is 1,785.37% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $125.00 |
| Price Target Difference | 1,785.37% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 1, 2025. It was a reverse split with a ratio of 1:25.
| Last Split Date | Dec 1, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |